Abstract:Pulmonary alveolar proteinosis (PAP) is an umbrella term used to refer to a pulmonary syndrome which is characterized by excessive accumulation of surfactant in the lungs of affected individuals. In general, PAP is a rare lung disease affecting children and adults, although its prevalence and incidence is variable among different countries. Even though PAP is a rare disease, it is a prime example on how modern medicine can lead to new therapeutic concepts, changing ways and techniques of (genetic) diagnosis which ultimately led into personalized treatments, all dedicated to improve the function of the impaired lung and thus life expectancy and quality of life in PAP patients. In fact, new technologies, such as new sequencing technologies, gene therapy approaches, new kind and sources of stem cells and completely new insights into the ontogeny of immune cells such as macrophages have increased our understanding in the onset and progression of PAP, which have paved the way for novel therapeutic concepts for PAP and beyond. As of today, classical monocyte-derived macrophages are known as important immune mediator and immune sentinels within the innate immunity. Furthermore, macrophages (known as tissue resident macrophages (TRMs)) can also be found in various tissues, introducing e. g. alveolar macrophages in the broncho-alveolar space as crucial cellular determinants in the onset of PAP and other lung disorders. Given recent insights into the onset of alveolar macrophages and knowledge about factors which impede their function, has led to the development of new therapies, which are applied in the context of PAP, with promising implications also for other diseases in which macrophages play an important role. Thus, we here summarize the latest insights into the various forms of PAP and introduce new pre-clinical work which is currently conducted in the framework of PAP, introducing new therapies for children and adults who still suffer from this severe, potentially life-threatening disease. Pulmonale Alveolar Proteinose (PAP) ist ein Überbegriff für ein pulmonales Syndrom, das durch die übermäßige Akkumulation von Surfactant in den Lungen von betroffenen Patienten gekennzeichnet ist. PAP ist eine seltene Erkrankung, die sowohl Kinder als auch Erwachsene betrifft und deren Prävalenz und Inzidenz stark zwischen verschiedenen Ländern variiert. Obwohl die PAP eine seltene Erkrankung ist, so ist diese Krankheit ein gutes Beispiel wie Fortschritte in der modernen Medizin zu neuen therapeutischen Ansätzen und veränderten Methoden und Techniken in der genetischen Diagnostik führen, welches schlussendlich die Lungenfunktion der Patienten verbessern und somit eine höhere Lebenserwartung und gesteigerte Lebensqualität der Patienten ermöglichen. Zum besseren Verständnis in der Krankheitsentstehung haben aktuelle Technologien wie neuste Genomsequenzierung, moderne Gentherapieansätze, Möglichkeiten der Stammzellgewinnung sowie neuste Erkenntnisse in der Ontogenese von Immunzellen wie beispielsweise Makrophagen, maßgeblich dazu beigetragen die Lebensqualität von Patienten zu verbessern. Damit wurde der Weg für neue therapeutische Ansätze in der Behandlung von PAP geebnet, aber auch ein großer Beitrag zum allgemeinen wissenschaftlichen Verständnis erbracht. Im Bereich der PAP und als wesentliche Grundlage in der Krankheitsentstehung haben sich klassische, aus Monozyten differenzierte Makrophagen als wichtiger Wächter und Modulator der angeborenen Immunabwehr etabliert. Darüber hinaus sind auch gewebespezifische Makrophagen (tissue resident macrophages, TRM) in nahezu allen Geweben, so auch der Lunge, des menschlichen Körpers zu finden und gewinnen im medizinischen Kontext zunehmend an Bedeutung. So spielen beispielsweise die Alveolar-Makrophagen, die im broncho-alveolären Raum angesiedelt sind, eine tragende Rolle in der Pathophysiologie -Abstract Truncated-

Pulmonary transplantation of macrophage progenitors as effective and long-lasting therapy for hereditary pulmonary alveolar proteinosis

Pulmonary Transplantation of Human Induced Pluripotent Stem Cell-derived Macrophages Ameliorates Pulmonary Alveolar Proteinosis

Understanding the Impact of Macrophages on Lung Transplant Outcomes

Pulmonary Alveolar Proteinosis and new therapeutic concepts

Single Lung Transplantation for Idiopathic Pulmonary Alveolar Proteinosis with Intraoperative Veno-Venous Extracorporeal Membrane Oxygenation Support

Alveolar Macrophages in Pulmonary Alveolar Proteinosis: Origin, Function, and Therapeutic Strategies

Profibrogenic macrophage-targeted delivery of mitochondrial protector via exosome formula for alleviating pulmonary fibrosis

Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency

Lung cell transplantation for pulmonary fibrosis

Lung Regeneration by Transplantation of Allogeneic Lung Progenitors Using a Safer Conditioning Regimen and Clinical-grade Reagents

Alveolar macrophage lipid burden correlates with clinical improvement in patients with Pulmonary Alveolar Proteinosis

Generation of macrophage containing alveolar organoids derived from human pluripotent stem cells for pulmonary fibrosis modeling and drug efficacy testing

A Novel Approach for Investigating Profibrotic Macrophage Polarization Using Murine Precision-Cut Lung Slices

Rapamycin and Hyperoside-Co-loaded Macrophage Delivery System Enhanced Pulmonary Fibrosis Therapy by Autophagy Upregulation and Epithelial-to-Mesenchymal Transition Inhibition

Prolonged xenokidney graft survival in sensitized NHP recipients by expression of multiple human transgenes in a triple knockout pig

Macrophage expressed tartrate‐resistant acid phosphatase 5 promotes pulmonary fibrosis progression

Successful bilateral lung transplantation in a five-year-old child with pulmonary interstitial fibrosis caused by an ABCA3 gene mutation

A novel ex vivo approach for investigating profibrotic macrophage polarization using murine precision-cut lung slices

Mesenchymal stem cell pretreatment of non-heart-beating-donors in experimental lung transplantation

Mitochondrial Transplantation Ameliorates Pulmonary Fibrosis by Suppressing Myofibroblast Activation

Autologous transplantation of P63 + lung progenitor cells for chronic obstructive pulmonary disease therapy